摘要
目的观察盐酸小檗碱(BBR)治疗非酒精性脂肪肝并血脂紊乱的的疗效与安全性。方法47例非酒精性脂肪肝并血脂紊乱患者服用盐酸小檗碱0.5g/次,3次/天,疗程8周,治疗前后测定肝肾功能、血糖及血脂水平等指标。结果BBR治疗后,患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)较治疗前明显下降(P<0.01),高密度脂蛋白胆固醇(HDL-C)变化不显著。血清ALT、空腹血糖(FBG)、餐后2h血糖(PBG)、糖化血红蛋白(HbA1c)治疗后显著下降(P<0.05),而AST、TBiL及肾功Cr、BUN无明显改变。观察期间无明显不良反应。结论BBR治疗非酒精性脂肪肝并血脂紊乱疗效确切安全,且具有降酶、降糖作用。
Objective To evaluate the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease （NAFLD） with dyslipidemia. Methods Forty seven patients with NAFLD and dyslipidemia were treated with berberine （1.5g daily） for 8 weeks. Before and after 8 weeks of treatment,the change of serum cholesterol （TC）,triglyceride （TG）,low-density lipo- protein-cholesterol（LDL-c） high-density lipoprotein-cholesterol（HDL-c）, ALT, AST, TBiL, FBG, PBG, HbAlc, Cr, BUN were detected respectively. Side effect was also observed during the experiment. Results The levels of TC, TG, LDL-c, ALT,FBG, PBG, HbA1c were obviously reduced at the end point compared with the baseline, whereas no significant change of HDL-c AST,TBiL,Cr and BUN was found, no severe side effects occurred during the experiment. Conclusion Berberine is effective and safe in the treatment of NAFLD with dyslipidemia and have the role in regulation of impaired fat and glucose metabolism.
出处
《重庆医学》
CAS
CSCD
北大核心
2009年第10期1215-1216,1218,共3页
Chongqing medicine
关键词
非酒精性脂肪肝
小檗碱
血脂紊乱
non-alcoholic fatty liver disease
berberine
cholesterol
triglyceride
blood glucose
